Report Library
All ReportsDatamonitor Meningococcal Vaccines KOL Interview
July 12, 2016
Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to determine this physician's
views on marketed and pipeline meningococcal vaccines.
If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).
Highlights
For our disclosures, please read the Biomedtracker Research Standards.
If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).
Highlights
- Advantage of tetravalent conjugated vaccines over unconjugated vaccines.
- Expansion of meningococcal vaccination beyond the 11-21 years age group.
- Comparison of Menveo and Menactra tetravalent vaccines
- Serotype B vaccines Bexsero and Trumenba
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Meningococcal Vaccines and Other Meningococcus-Specific Agents (Antibacterial) |